Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies

PURPOSE: In two 24‐week migraine prevention studies in Japan, erenumab was associated with significantly greater reductions in migraine frequency versus placebo over Weeks 13–24 (primary endpoint). This post hoc analysis evaluated the onset of efficacy within the first 4 weeks after the initiation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Koichi, Takeshima, Takao, Sakai, Fumihiko, Imai, Noboru, Matsumori, Yasuhiko, Tatsuoka, Yoshihisa, Numachi, Yotaro, Yoshida, Ryuji, Peng, Cheng, Mikol, Daniel D., Lima, Gabriel Paiva da Silva, Cheng, Sunfa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933787/
https://www.ncbi.nlm.nih.gov/pubmed/35201674
http://dx.doi.org/10.1002/brb3.2526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933787/
https://www.ncbi.nlm.nih.gov/pubmed/35201674
http://dx.doi.org/10.1002/brb3.2526

Ejemplares similares